- Home
- CERT vs NAMS Comparison
CERT vs NAMS Comparison
Compare CERT & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERT
- NAMS
- Stock Information
- Founded
- CERT 2008
- NAMS 2019
- Country
- CERT United States
- NAMS Netherlands
- Employees
- CERT N/A
- NAMS N/A
- Industry
- CERT Retail: Computer Software & Peripheral Equipment
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- CERT Technology
- NAMS Health Care
- Exchange
- CERT Nasdaq
- NAMS Nasdaq
- Market Cap
- CERT 2.3B
- NAMS 2.2B
- IPO Year
- CERT 2020
- NAMS N/A
- Fundamental
- Price
- CERT $11.36
- NAMS $18.11
- Analyst Decision
- CERT Buy
- NAMS Strong Buy
- Analyst Count
- CERT 6
- NAMS 6
- Target Price
- CERT $15.60
- NAMS $42.83
- AVG Volume (30 Days)
- CERT 1.7M
- NAMS 694.5K
- Earning Date
- CERT 05-05-2025
- NAMS 05-08-2025
- Dividend Yield
- CERT N/A
- NAMS N/A
- EPS Growth
- CERT N/A
- NAMS N/A
- EPS
- CERT N/A
- NAMS N/A
- Revenue
- CERT $394,498,000.00
- NAMS $47,140,000.00
- Revenue This Year
- CERT $11.47
- NAMS N/A
- Revenue Next Year
- CERT $9.03
- NAMS N/A
- P/E Ratio
- CERT N/A
- NAMS N/A
- Revenue Growth
- CERT 9.37
- NAMS 586.97
- 52 Week Low
- CERT $8.64
- NAMS $14.06
- 52 Week High
- CERT $17.76
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- CERT 41.96
- NAMS 47.80
- Support Level
- CERT $11.17
- NAMS $16.79
- Resistance Level
- CERT $11.75
- NAMS $19.58
- Average True Range (ATR)
- CERT 0.42
- NAMS 0.94
- MACD
- CERT -0.06
- NAMS -0.12
- Stochastic Oscillator
- CERT 24.00
- NAMS 47.07
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.